Patents Assigned to JENNEWEIN BIOTECHNOLOGIE GMBH
-
Patent number: 11168105Abstract: The present application discloses a process for the purification of a neutral human milk oligosaccharide (neutral HMO). The process uses simulated moving bed (SMB) chromatography which allows the continuous purification of large quantities of HMOs with high purity. Contrary to chemical synthesis routes of neutral HMOs, and their subsequent purification, the presented process allows the provision of HMOs free of noxious chemicals, such as e.g. trace amounts of heavy metals or organic solvents. The individual neutral HMO product may be obtained in solid form by spray drying or as a concentrated syrup. The provided neutral HMO is very well-suited for use in food applications.Type: GrantFiled: June 13, 2019Date of Patent: November 9, 2021Assignee: JENNEWEIN BIOTECHNOLOGIE GMBHInventors: Stefan Jennewein, Markus Helfrich
-
Patent number: 11066685Abstract: The present invention relates to a process for producing a monosaccharide, e.g. L-fucose, in free form using a microbial fermentation process. The used microorganism exhibits hydrolase activity on nucleotide-activated sugars and releases the monosaccharide in an unmodified free form. The free monosaccharide is retrieved from the supernatant of the cultivated microorganism.Type: GrantFiled: January 29, 2016Date of Patent: July 20, 2021Assignee: Jennewein Biotechnologie GmbHInventors: Stefan Jennewein, Katja Parschat
-
Patent number: 10882880Abstract: The present application discloses a simple process for the purification of neutral human milk oligosaccharides (HMOs) produced by microbial fermentation. The process uses a combination of cationic ion exchanger treatment, an anionic ion exchanger treatment, and a nanofiltration and/or electrodialysis step, which allows efficient purification of large quantities of neutral HMOs at high purity. Contrary to the purification currently used in fermentative production of neutral HMOs, the presented process allows the provision of HMOs without the need of a chromatographic separation. The so purified HMOs may be obtained in solid form by spray drying, as crystalline material or as sterile filtered concentrate. The provided HMOs are free of proteins and recombinant material originating from the used recombinant microbial strains and thus very well-suited for use in food, medical food and feed (e.g. pet food) applications.Type: GrantFiled: February 15, 2019Date of Patent: January 5, 2021Assignee: Jennewein Biotechnologie GmbHInventor: Stefan Jennewein
-
Publication number: 20190309336Abstract: The present invention relates to a method for producing fucosylated oligosaccharides by using a recombinant prokaryotic host cell that is cultivated on a gluconeogenic substrate, as well as to the host cell and its use. The host cell is genetically modified in that the activity of a fructose-6-phosphate converting enzyme is abolished or lowered, and the transport of the produced fucosylated oligosaccharide through the cell membrane is facilitated by an exogenous transport protein.Type: ApplicationFiled: October 24, 2017Publication date: October 10, 2019Applicant: JENNEWEIN BIOTECHNOLOGIE GMBHInventors: Stefan JENNEWEIN, Dirk WARTENBERG, Katja PARSCHAT
-
Patent number: 10435427Abstract: The present application discloses a process for the purification of a neutral human milk oligosaccharide (neutral HMO). The process uses simulated moving bed (SMB) chromatography which allows the continuous purification of large quantities of HMOs with high purity. Contrary to chemical synthesis routes of neutral HMOs, and their subsequent purification, the presented process allows the provision of HMOs free of noxious chemicals, such as e.g. trace amounts of heavy metals or organic solvents. The individual neutral HMO product may be obtained in solid form by spray drying or as a concentrated syrup. The provided neutral HMO is very well-suited for use in food applications.Type: GrantFiled: October 2, 2014Date of Patent: October 8, 2019Assignee: Jennewein Biotechnologie GmbHInventors: Stefan Jennewein, Markus Helfrich
-
Patent number: 10377787Abstract: The present application discloses a simple process for the purification of neutral human milk oligosaccharides (HMOs) produced by microbial fermentation. The process uses a combination of a cationic ion exchanger treatment, an anionic ion exchanger treatment, and a nanofiltration and/or electrodialysis step, which allows efficient purification of large quantities of neutral HMOs at high purity. Contrary to the purification currently used in fermentative production of neutral HMOs, the presented process allows the provision of HMOs without the need of a chromatographic separation. The so purified HMOs may be obtained in solid form by spray drying, as crystalline material or as sterile filtered concentrate. The provided HMOs are free of proteins and recombinant material originating from the used recombinant microbial strains and thus very well-suited for use in food, medical food and feed (e.g. pet food) applications.Type: GrantFiled: December 23, 2014Date of Patent: August 13, 2019Assignee: JENNEWEIN BIOTECHNOLOGIE GMBHInventor: Stefan Jennewein
-
Patent number: 9968625Abstract: The present invention relates to synthetic fucosylated oligosaccharide for use in the treatment or prophylaxis of an infection with a Norwalk-like Virus or Rotavirus of a mam-mal, wherein the synthetic fucosylated oligosaccharide comprises a non-reducing end and an reducing end, wherein the reducing end comprises a first carbohydrate unit consisting of a galactose (Gal) linked via a ?1-4 glycosidic bond to a glucose (Glc), and wherein the non-reducing end comprises a second carbohydrate unit linked via a ?1-3 glycosidic bond to the first carbohydrate unit of the reducing end, and wherein the second carbohydrate unit comprises a) at least one or more of a fucose (Fucose) and a Galactose (Gal), and b) at least one or more of a N-acetylglucosamine (GlcNAc) or a N-acetylgalactosamine (GalNAc).Type: GrantFiled: August 19, 2015Date of Patent: May 15, 2018Assignee: Jennewein Biotechnologie GmbHInventor: Stefan Jennewein
-
Patent number: 9938549Abstract: The present invention relates to a process for producing a monosaccharide using a microorganism. The microorganism possesses a glycosyltransferase and a glycosidase which work together to synthesize a desired monosaccharide in free form by using an endogenous provided nucleotide activated monosaccharide, glycosylate a suitable acceptor substrate and release the desired monosaccharide by a hydrolysis reaction. The required acceptor substrate for the reaction is recycled and only needed in catalytic amounts. The monosaccharide is produced in free from and is retrieved from the supernatant of the cultivated microorganism.Type: GrantFiled: April 29, 2015Date of Patent: April 10, 2018Assignee: Jennewein Biotechnologie GmbHInventors: Stefan Jennewein, Katja Parschat
-
Patent number: 9611285Abstract: The present invention relates to nucleic acid and amino acid sequences from Escherichia coli serogroup O126, coding for/representing a novel alpha-1,2-fucosyltransferase. The invention also provides uses and methods for using the alpha-1,2-fucosyltransferase to generate fucosylated products, such as oligosaccharides, (glyco)proteins, or (glyco)lipids, in particular oligosaccharides found in human milk, such as 2?-fucosyllactose.Type: GrantFiled: July 19, 2013Date of Patent: April 4, 2017Assignee: Jennewein Biotechnologie GmbHInventors: Julia Parkot, Eric Huefner, Stefan Jennewein, Lothar Elling, Leonie Engels
-
Patent number: 9512433Abstract: The present invention relates to a cell to be stably cultured in a medium, which cell is adjusted for the production of oligosaccharides, the cell being transformed to comprise at least one nucleic acid sequence coding for an enzyme involved in oligosaccharide synthesis. In addition the cell is transformed to comprise at least one nucleic acid sequence coding for a protein of the sugar efflux transporter family, a functional homolog or derivative thereof. Further, the invention concerns a method for the production of oligosaccharides involving above cell.Type: GrantFiled: December 9, 2013Date of Patent: December 6, 2016Assignee: JENNEWEIN BIOTECHNOLOGIE GmbHInventors: Stefan Jennewein, Eric Huefner, Julia Parkot
-
Publication number: 20160333042Abstract: The present application discloses a simple process for the purification of neutral human milk oligosaccharides (HMOs) produced by microbial fermentation. The process uses a combination of a cationic ion exchanger treatment, an anionic ion exchanger treatment, and a nanofiltration and/or electrodialysis step, which allows efficient purification of large quantities of neutral HMOs at high purity. Contrary to the purification currently used in fermentative production of neutral HMOs, the presented process allows the provision of HMOs without the need of a chromatographic separation. The so purified HMOs may be obtained in solid form by spray drying, as crystalline material or as sterile filtered concentrate. The provided HMOs are free of proteins and recombinant material originating from the used recombinant microbial strains and thus very well-suited for use in food, medical food and feed (e.g. pet food) applications.Type: ApplicationFiled: December 23, 2014Publication date: November 17, 2016Applicant: JENNEWEIN BIOTECHNOLOGIE GMBHInventor: Stefan JENNEWEIN
-
Patent number: 9441211Abstract: The present invention relates to nucleic acid and amino acid sequences from Akkermansia muciniphila and from Bacteroides fragilis, coding for/representing novel alpha-1,3-fucosyltransferases. The invention also provides uses and methods for using the alpha-1,3-fucosyltransferases to generate fucosylated products, such as oligosaccharides, (glyco)proteins, or (glyco)lipids, in particular of 3-fucosyllactose.Type: GrantFiled: April 10, 2013Date of Patent: September 13, 2016Assignee: JENNEWEIN BIOTECHNOLOGIE GMBHInventors: Julia Parkot, Eric Hüfner, Stefan Jennewein
-
Publication number: 20160237104Abstract: The present application discloses a process for the purification of a neutral human milk oligosaccharide (neutral HMO). The process uses simulated moving bed (SMB) chromatography which allows the continuous purification of large quantities of HMOs with high purity. Contrary to chemical synthesis routes of neutral HMOs, and their subsequent purification, the presented process allows the provision of HMOs free of noxious chemicals, such as e.g. trace amounts of heavy metals or organic solvents. The individual neutral HMO product may be obtained in solid form by spray drying or as a concentrated syrup. The provided neutral HMO is very well-suited for use in food applications.Type: ApplicationFiled: October 2, 2014Publication date: August 18, 2016Applicant: Jennewein Biotechnologie GmbHInventors: Stefan JENNEWEIN, Markus HELFRICH
-
Publication number: 20160186223Abstract: The present invention relates to the use of one or more glycosidases in the process for the production and/or purification of a produced desired oligosaccharide. The process is preferably a microbial fermentation process using a host microorganism, which may also comprise nucleic acids expressing sugar catabolic pathway proteins suitable for the degradation of saccharides otherwise hindering the purification of the desired oligosaccharide.Type: ApplicationFiled: March 10, 2016Publication date: June 30, 2016Applicant: JENNEWEIN BIOTECHNOLOGIE GMBHInventor: Stefan Jennewein
-
Publication number: 20150352133Abstract: The present invention relates to synthetic fucosylated oligosaccharide for use in the treatment or prophylaxis of an infection with a Norwalk-like Virus or Rotavirus of a mam-mal, wherein the synthetic fucosylated oligosaccharide comprises a non-reducing end and an reducing end, wherein the reducing end comprises a first carbohydrate unit consisting of a galactose (Gal) linked via a ?1-4 glycosidic bond to a glucose (Glc), and wherein the non-reducing end comprises a second carbohydrate unit linked via a ?1-3 glycosidic bond to the first carbohydrate unit of the reducing end, and wherein the second carbohydrate unit comprises a) at least one or more of a fucose (Fucose) and a Galactose (Gal), and b) at least one or more of a N-acetylglucosamine (GlcNAc) or a N-acetylgalactosamine (GalNAc).Type: ApplicationFiled: August 19, 2015Publication date: December 10, 2015Applicant: JENNEWEIN BIOTECHNOLOGIE GMBHInventor: Stefan Jennewein
-
Publication number: 20150240277Abstract: The present invention relates to a process for producing a monosaccharide using a microorganism. The microorganism possesses a glycosyltransferase and a glycosidase which work together to synthesize a desired monosaccharide in free form by using an endogenous provided nucleotide activated monosaccharide, glycosylate a suitable acceptor substrate and release the desired monosaccharide by a hydrolysis reaction. The required acceptor substrate for the reaction is recycled and only needed in catalytic amounts. The monosaccharide is produced in free from and is retrieved from the supernatant of the cultivated microorganism.Type: ApplicationFiled: April 29, 2015Publication date: August 27, 2015Applicant: JENNEWEIN BIOTECHNOLOGIE GMBHInventors: Stefan Jennewein, Katja Parschat
-
Publication number: 20140120611Abstract: The present invention relates to a cell to be stably cultured in a medium, which cell is adjusted for the production of oligosaccharides, the cell being transformed to comprise at least one nucleic acid sequence coding for an enzyme involved in oligosaccharide synthesis. In addition the cell is transformed to comprise at least one nucleic acid sequence coding for a protein of the sugar efflux transporter family, a functional homolog or derivative thereof. Further, the invention concerns a method for the production of oligosaccharides involving above cell.Type: ApplicationFiled: December 9, 2013Publication date: May 1, 2014Applicant: JENNEWEIN BIOTECHNOLOGIE GmbHInventors: Stefan Jennewein, Eric Huefner, Julia Parkot
-
Patent number: 8652808Abstract: The present invention relates to a cell to be stably cultured in a medium, which cell is adjusted for the production of oligosaccharides, the cell being transformed to comprise at least one nucleic acid sequence coding for an enzyme involved in oligosaccharide synthesis. In addition the cell is transformed to comprise at least one nucleic acid sequence coding for a protein of the sugar efflux transporter family, a functional homolog or derivative thereof. Further, the invention concerns a method for the production of oligosaccharides involving above cell.Type: GrantFiled: November 30, 2011Date of Patent: February 18, 2014Assignee: Jennewein Biotechnologie GmbHInventors: Stefan Jennewein, Eric Huefner, Julia Parkot
-
Publication number: 20140024820Abstract: The present invention relates to nucleic acid and amino acid sequences from Escherichia coli serogroup O126, coding for/representing a novel alpha-1,2-fucosyltransferase. The invention also provides uses and methods for using the alpha-1,2-fucosyltransferase to generate fucosylated products, such as oligosaccharides, (glyco)proteins, or (glyco)lipids, in particular oligosaccharides found in human milk, such as 2?-fucosyllactose.Type: ApplicationFiled: July 19, 2013Publication date: January 23, 2014Applicant: Jennewein Biotechnologie GmbHInventors: Julia Parkot, Eric Huefner, Stefan Jennewein, Lothar Elling, Leonie Engels
-
Publication number: 20130217068Abstract: The present invention relates to nucleic acid and amino acid sequences from Akkermansia muciniphila and from Bacteroides fragilis, coding for/representing novel alpha-1,3-fucosyltransferases. The invention also provides uses and methods for using the alpha-1,3-fucosyltransferases to generate fucosylated products, such as oligosaccharides, (glyco)proteins, or (glyco)lipids, in particular of 3-fucosyllactose.Type: ApplicationFiled: April 10, 2013Publication date: August 22, 2013Applicant: JENNEWEIN BIOTECHNOLOGIE GMBHInventor: JENNEWEIN BIOTECHNOLOGIE GMBH